OncoTherapy Science, Inc. (TYO:4564)
Japan
· Delayed Price · Currency is JPY 23.00
-1.00 (-4.17%)
May 2, 2025, 3:30 PM JST
OncoTherapy Science Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Revenue | 707 | 610 | 1,134 | 1,153 | 332 | 316 | Upgrade
|
| Revenue Growth (YoY) | -21.53% | -46.21% | -1.65% | 247.29% | 5.06% | 12.86% | Upgrade
|
| Cost of Revenue | 1,271 | 1,465 | 1,810 | 2,770 | 1,689 | 2,108 | Upgrade
|
| Gross Profit | -564 | -855 | -676 | -1,617 | -1,357 | -1,792 | Upgrade
|
| Selling, General & Admin | 278 | 261 | 287 | 294 | 281 | 271 | Upgrade
|
| Other Operating Expenses | 4 | 4 | 144 | 142 | - | 126 | Upgrade
|
| Operating Expenses | 282 | 265 | 431 | 436 | 281 | 397 | Upgrade
|
| Operating Income | -846 | -1,120 | -1,107 | -2,053 | -1,638 | -2,189 | Upgrade
|
| Currency Exchange Gain (Loss) | -1 | -5 | -8 | -14 | -3 | 1 | Upgrade
|
| Other Non Operating Income (Expenses) | -19 | -12 | -18 | -5 | 1 | -9 | Upgrade
|
| EBT Excluding Unusual Items | -866 | -1,137 | -1,133 | -2,072 | -1,640 | -2,197 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -11 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 50 | Upgrade
|
| Asset Writedown | -152 | -154 | -21 | -547 | -10 | -165 | Upgrade
|
| Other Unusual Items | 2 | 5 | 38 | 49 | 90 | 86 | Upgrade
|
| Pretax Income | -1,016 | -1,286 | -1,116 | -2,570 | -1,560 | -2,237 | Upgrade
|
| Income Tax Expense | 2 | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Earnings From Continuing Operations | -1,018 | -1,288 | -1,118 | -2,571 | -1,561 | -2,238 | Upgrade
|
| Net Income | -1,018 | -1,288 | -1,118 | -2,571 | -1,561 | -2,238 | Upgrade
|
| Net Income to Common | -1,018 | -1,288 | -1,118 | -2,571 | -1,561 | -2,238 | Upgrade
|
| Shares Outstanding (Basic) | 248 | 213 | 193 | 187 | 176 | 163 | Upgrade
|
| Shares Outstanding (Diluted) | 248 | 213 | 193 | 187 | 176 | 163 | Upgrade
|
| Shares Change (YoY) | 19.95% | 10.45% | 2.76% | 6.31% | 8.14% | 10.54% | Upgrade
|
| EPS (Basic) | -4.11 | -6.05 | -5.80 | -13.71 | -8.85 | -13.73 | Upgrade
|
| EPS (Diluted) | -4.11 | -6.05 | -5.80 | -13.71 | -8.85 | -13.73 | Upgrade
|
| Free Cash Flow | - | -1,229 | -798 | -2,529 | -1,805 | -2,405 | Upgrade
|
| Free Cash Flow Per Share | - | -5.78 | -4.14 | -13.49 | -10.24 | -14.75 | Upgrade
|
| Gross Margin | -79.77% | -140.16% | -59.61% | -140.24% | - | - | Upgrade
|
| Operating Margin | -119.66% | -183.61% | -97.62% | -178.06% | -493.37% | -692.72% | Upgrade
|
| Profit Margin | -143.99% | -211.15% | -98.59% | -222.98% | -470.18% | -708.23% | Upgrade
|
| Free Cash Flow Margin | - | -201.47% | -70.37% | -219.34% | -543.67% | -761.08% | Upgrade
|
| EBITDA | - | - | -1,091 | -2,037 | -1,589 | -2,150 | Upgrade
|
| EBITDA Margin | - | - | -96.21% | -176.67% | - | - | Upgrade
|
| D&A For EBITDA | - | - | 16 | 16 | 49 | 39 | Upgrade
|
| EBIT | -846 | -1,120 | -1,107 | -2,053 | -1,638 | -2,189 | Upgrade
|
| EBIT Margin | -119.66% | -183.61% | -97.62% | -178.06% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.